We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





World’s Only Hygienic Digital Urine Test Launched

By LabMedica International staff writers
Posted on 28 Jan 2019
The world’s only hygienic, easy-to-use and accurate digital point-of-care urine test named Urine Testing System was launched at Arab Health 2019 by Clinical Design (Penryn, Cornwall, UK). More...
The digital point-of-care urine test has been designed to improve the entire process from receiving the sample and recording results, to analysis in the laboratory.

The highly intuitive system features sealed, leak-proof samples, automatically timed readings and the ability to save digital results directly into the patient’s electronic health record. No decanting is required, reducing the risk of contamination and false positive samples being sent to laboratories. Digital readings are also more accurate compared to manual urinalysis as they eliminate variation in subjective analysis and the risk of error during manual recording.

Urine Testing System works seamlessly as a closed integrated system and includes a patented, single-use cap containing reagent pads to test ten parameters: leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketone, bilirubin and glucose. Once the patient has collected the urine sample, the healthcare professional simply connects UTS-10 Cap; creating a sealed, leak-proof module. This UTS module is then loaded into the UTS Digital Analyzer and the automatically timed, digital results are shown on the integrated LCD screen or in the UTS Desktop Software if connected to a computer.

The sample can be disposed of in clinical waste or be sent to the laboratory with no need to decant. It is specially designed to fit in standard laboratory racking – and can be purchased with or without boric acid depending on laboratory requirements. The current test takes approximately one to two minutes and risks include spillage of a contaminated sample, as well as human errors during analysis and/or the manual recording into a patient's records.

“We have developed a simple integrated system that increases the efficacy of patient point-of-care urine testing and improves first-time diagnosis. It is the only closed urine testing system available anywhere in the world and we are delighted to be able to showcase it at Arab Health 2019,” said Oliver Blackwell, CEO of Clinical Design.

Related Links:
Clinical Design

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
HPV Molecular Test
BD Onclarity HPV Assay
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.